Tuesday, June 16, 2026

HIDING Piglet: Kim Jong Un Is Too Scared To Meet Trump, Snubbing Global Diplomacy For Cowardly Silence

Trump seeks a meeting with Kim Jong Un, but North Korea remains silent, raising questions about potential talks ahead.

6G Preview? KT Demonstrates AI-Driven CSI Compression on a Qualcomm Snapdragon Platform, Boosting Downlink by ~50%

KT demonstrates AI-based wireless tech with Qualcomm and Rohde & Schwarz, improving downlink speeds by 50% for next-gen networks.

Mac Users Beware: New Malware Can Steal Your Data in Just 36 Hours

A report reveals a 28% rise in info-stealing malware targeting macOS users, urging enhanced security measures against sophisticated attacks.

Tag: clinical trials

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

CT-P72/ABP-102: The Next Big Breakthrough in HER2 Cancer Treatment?

Celltrion's CT-P72/ABP-102 shows strong efficacy against HER2 tumors, promising for treating various cancers with reduced toxicity.

How Hyundai BioScience’s XAFTY Could Revolutionize Ebola Treatment: A Free Supply Proposal

Hyundai Bio USA proposes to provide antiviral candidate XAFTY for free to Ebola-affected countries, aiming to combat the disease urgently.

How International Collaboration is Revolutionizing Infectious Disease Research in Asia

Korea's Disease Control Agency establishes a framework for local medical institutions to join international clinical trials for infectious diseases.

GC Biopharma Unveils mRNA Vaccine Strategy at Seoul Pandemic X Summit 2026: What’s Next for COVID-19?

GC Biopharma presents its mRNA vaccine strategy at the Seoul Pandemic X Summit 2026, focusing on rapid responses to future pandemics.

Stem Cell Therapies Face Long Road to Market Despite Decades of Promise

Stem cell therapies show promise for treating diseases, but face significant commercialization challenges, including quality control and funding.

U.S. FDA to Streamline IND Process: What It Means for Asian Biotech Competitiveness in 2027

The U.S. aims to streamline drug approval processes to compete with China and Australia in attracting clinical trials, enhancing biotech growth.

AstraZeneca’s Elecoglipron: Can This New Weight Loss Pill Compete with GLP-1 Giants?

AstraZeneca's new weight-loss pill, elecoglipron, shows promising results in trials, competing with existing obesity treatments.

Sam Chun Dang Pharm Wins EMA Approval for Phase 1 Trial of Oral Insulin Candidate SCD0503

Samchundang Pharmaceutical's oral insulin candidate 'SCD0503' received final approval for Phase 1 clinical trials from EMA.

Celltrion Moves CT-G32 Into Final Preclinical Stage as Global Obesity Trial Preparation Accelerates

Celltrion advances CT-G32, a next-gen obesity treatment, targeting multiple pathways to enhance weight loss while preserving muscle mass.

Seoul St. Mary’s Prof. Jang Ki-yuk Selected as Sole Applied Medicine Researcher in National Leader Program

Prof. Jang Ki-yuk of Seoul St. Mary's Hospital receives $5.2M for cardiovascular disease research, focusing on plaque regression.

Metavia Highlights Strong Early Weight-Loss Data for DA-1726 at EASL 2026

MetaVia's obesity treatment candidate 'DA-1726' shows safety and weight loss effects in Phase 1 trials after 54 days.

HLB to Spotlight Liver and Bile Duct Cancer Pipeline at ASCO 2026 With Standalone Global Booth

HLB will showcase liver cancer drug candidates at ASCO 2026, including promising combination therapies and precision medicine studies.

Lunit to Present Five AI Biomarker Studies at ASCO 2026 Highlighting Expanded Clinical Applications

Lunit will present five AI studies at ASCO 2026, showcasing biomarker analysis for cancer treatment and patient response prediction.

Study Outlines Clinical Potential of Rejuvenating Retinal Cells to Treat Age-Related Vision Loss

Researchers reveal a breakthrough in treating eye diseases by rejuvenating aged cells, potentially restoring vision through epigenetic reprogramming.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.